Liver transplant drug trial halted early – only 6 patients enrolled
NCT ID NCT05514119
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether the drug fenofibrate could prevent a type of bile duct damage called ischemic cholangiopathy in people who received a liver from a donor after circulatory death. Only 6 participants were enrolled before the trial was terminated early. The main goal was to see if patients could tolerate the medication without serious side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Fenofibrate (Lofibra), a medication taken as a 160 mg pill once daily for 12 weeks
- What this could lead to
- If it worked, fenofibrate could help prevent bile duct damage in people who receive a liver from a donor after circulatory death, improving transplant success.
- What could go wrong
- The trial was terminated early and only enrolled 6 people, so results are very limited. Fenofibrate may cause side effects like kidney issues or rejection, and its benefit is unproven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER TRANSPLANT are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic Arizona
Phoenix, Arizona, 85254, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can personalized antibiotics outsmart resistant bacteria in liver transplants?
- Blood-Clotting showdown: which device best guides bleeding care in High-Risk patients?
- Could a daily pill shield transplant patients from a common virus?
- Which liver biopsy needle delivers the best tissue? a Head-to-Head comparison
- Transplant breakdown? new study checks organ fluid for hidden germs
- New study aims to catch transplant complications early with blood and urine tests